Compare ACLS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACLS | SUPN |
|---|---|---|
| Founded | 1995 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.8B |
| IPO Year | 2000 | 2012 |
| Metric | ACLS | SUPN |
|---|---|---|
| Price | $86.08 | $51.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $102.25 | $61.60 |
| AVG Volume (30 Days) | 605.3K | ★ 754.8K |
| Earning Date | 02-17-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.25 | N/A |
| Revenue | ★ $853,135,000.00 | $681,539,000.00 |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | $6.84 | $22.15 |
| P/E Ratio | $20.26 | ★ N/A |
| Revenue Growth | N/A | ★ 4.54 |
| 52 Week Low | $40.40 | $29.16 |
| 52 Week High | $102.93 | $57.65 |
| Indicator | ACLS | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 43.04 | 61.38 |
| Support Level | $79.35 | $47.29 |
| Resistance Level | $91.01 | $49.71 |
| Average True Range (ATR) | 4.53 | 1.40 |
| MACD | -1.34 | 0.05 |
| Stochastic Oscillator | 26.40 | 100.00 |
Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.